Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Current Assets (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Current Assets over the past 10 years, most recently at $23.5 million for Q4 2023.

  • For Q4 2023, Current Assets fell 60.87% year-over-year to $23.5 million; the TTM value through Dec 2023 reached $23.5 million, down 60.87%, while the annual FY2023 figure was $23.5 million, 60.87% down from the prior year.
  • Current Assets for Q4 2023 was $23.5 million at Corbus Pharmaceuticals Holdings, down from $31.2 million in the prior quarter.
  • Over five years, Current Assets peaked at $130.3 million in Q1 2021 and troughed at $23.5 million in Q4 2023.
  • A 5-year average of $73.4 million and a median of $75.3 million in 2019 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: surged 141.32% in 2020 and later crashed 60.87% in 2023.
  • Year by year, Current Assets stood at $38.2 million in 2019, then surged by 141.32% to $92.1 million in 2020, then grew by 8.83% to $100.2 million in 2021, then plummeted by 39.94% to $60.2 million in 2022, then crashed by 60.87% to $23.5 million in 2023.
  • Business Quant data shows Current Assets for CRBP at $23.5 million in Q4 2023, $31.2 million in Q3 2023, and $38.3 million in Q2 2023.